:: دوره 6، شماره 3 - ( تابستان - 1397 ) ::
دوره 6 شماره 3 صفحات 91-99 برگشت به فهرست نسخه ها
اثرات سمّیت متامفتامین بر سیستم عصبی
ساناز هادی‌زاده عصار* ، محمد حسینی شریف‌آباد، مریم یادگاری
گروه علوم تشریح و بیولوژی، دانشگاه علوم پزشکی و خدمات بهداشتی -درمانی شهید صدوقی، یزد، ایران ، sanaz.hadizade92@gmail.com
چکیده:   (625 مشاهده)

مقدمه: متامفتامین دارویی است که بسیار اعتیادآور، توهم‌زا و سایکواکتیو است. در کنار ماری‌جوانا دومین ماده مخدری است که به طور وسیعی در سراسر جهان به‌ویژه توسط جوانان و نوجوانان مورد استفاده قرار می‌گیرد. مصرف گسترده متامفتامین باب جدیدی در آسیب‌های اجتماعی گشوده است. مشخص شده است که این ترکیبات دارای اثرات سمی بر سیستم عصبی مرکزی هستند. مصرف مکرر متامفتامین سبب آسیب به پایانه‌های عصبی دوپامینرژیک و سروتونرژیک در نواحی مختلف مغز شود. اختلال در حافظه و یادگیری، اضطراب و افسردگی و نیز اختلالات حرکتی نظیر بیماری پارکینسون از جمله اثرات سمی این دارو بر سیستم عصبی هستند. علاوه بر این شواهد نشان می‌دهد که این ترکیب می‌تواند باعث اسکیزوفرنی، اختلالات شناختی و اختلالات حرکتی در برخی از مصرف‌کنندگان شود. علی‌رغم عوارض مخرب ایجاد شده توسط متامفتامین، مکانیسم اثر این ماده هنوز شناسایی نشده و چالش بزرگی جهت راهکارهای درمانی به وجود آورده است. نتیجه‌گیری: امروزه مصرف متامفتامین به‌شدت در بین جوانان و نوجوانان در حال افزایش است. دانش و آگاهی کافی پیرامون عوارض فاجعه‌بار و جبران‌ناپذیر این دارو می‌تواند از آسیب‌های جدی بر سلامت عمومی پیشگیری کند.

واژه‌های کلیدی: متامفتامین، سیستم عصبی مرکزی، سیستم عصبی محیطی
متن کامل [PDF 490 kb]   (761 دریافت)    
نوع مطالعه: مروری | موضوع مقاله: نوروفارماکولوژی
فهرست منابع
1. Kamali Ardakani R, Nahangi H, Yadegari M, Hosseini-Sharifabad M. The effects of long-term administration of methamphetamine on the cerebellum of the male mice: a stereological study. Shefaye Khatam. 2014; 2(4): 37-45. [DOI:10.18869/acadpub.shefa.2.4.37]
2. Rusyniak DE. Neurologic manifestations of chronic methamphetamine abuse. Psychiatr Clin North Am. 2011; 29(3): 641-55. [DOI:10.1016/j.ncl.2011.05.004]
3. Won S, Hong RA, Shohet RV, Seto TB, Parikh NI. Methamphetamine‐associated cardiomyopathy. Clin Cardiol. 2013; 36(12): 737-42. [DOI:10.1002/clc.22195]
4. Allerton M, Blake W. The "Party drug" crystal methamphetamine: risk factor for the acquisition of HIV. Perm J. 2008; 12(1): 56-8. [DOI:10.7812/TPP/07-127]
5. Santos AP, Wilson AK, Hornung CA, Polk Jr HC, Rodriguez JL, Franklin GA. Methamphetamine laboratory explosions: a new and emerging burn injury. J Burn Care Res. 2005; 26(3): 228-32.
6. Alam-Mehrjerdi Z, Mokri A, Dolan K. Methamphetamine use and treatment in Iran: a systematic review from the most populated Persian gulf country. Asian J Psychiatr. 2015; 16: 17-25. [DOI:10.1016/j.ajp.2015.05.036]
7. Thanos PK, Kim R, Delis F, Ananth M, Chachati G, Rocco MJ, et al. Chronic methamphetamine effects on brain structure and function in rats. PloS One. 2016; 11(6): e0155457. [DOI:10.1371/journal.pone.0155457]
8. Herman-Stahl MA, Krebs CP, Kroutil LA, Heller DC. Risk and protective factors for nonmedical use of prescription stimulants and methamphetamine among adolescents. J Adolesc Health. 2006; 39(3): 374-80. [DOI:10.1016/j.jadohealth.2006.01.006]
9. Karila L, Weinstein A, Aubin HJ, Benyamina A, Reynaud M, Batki SL. Pharmacological approaches to methamphetamine dependence: a focused review. Br J Clin Pharmacol. 2010; 69(6): 578-92. [DOI:10.1111/j.1365-2125.2010.03639.x]
10. Prakash MD, Tangalakis K, Antonipillai J, Stojanovska L, Nurgali K, Apostolopoulos V. Methamphetamine: effects on the brain, gut and immune system. Pharmacol Res. 2017; 120: 60-7. [DOI:10.1016/j.phrs.2017.03.009]
11. Marshall JF, O'Dell SJ. Methamphetamine influences on brain and behavior: unsafe at any speed? Trends Neurosci. 2012; 35(9): 536-45. [DOI:10.1016/j.tins.2012.05.006]
12. Killinger B, Shah M, Moszczynska A. Co-administration of betulinic acid and methamphetamine causes toxicity to dopaminergic and serotonergic nerve terminals in the striatum of late adolescent rats. J Neurochem. 2014; 128(5): 764-75. [DOI:10.1111/jnc.12496]
13. Suzuki O, Hattori H, Asano M, Oya M, Katsumata Y. Inhibition of monoamine oxidase by d-methamphetamine. Biochem Pharmacol. 1980; 29(14): 2071-3. [DOI:10.1016/0006-2952(80)90493-1]
14. Kitanaka J, Kitanaka N, Takemura M. Modification of monoaminergic activity by MAO inhibitors influences methamphetamine actions. Drug Target Insights. 2006; 1: 19-28. [DOI:10.1177/117739280600100001]
15. Ressler KJ, Nemeroff CB. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress Anxiety. 2000; 12(1) :2-19. https://doi.org/10.1002/1520-6394(2000)12:1+<2::AID-DA2>3.0.CO;2-4 [DOI:10.1002/1520-6394(2000)12:1+3.0.CO;2-4]
16. Moszczynska A, Callan SP. Molecular, behavioral, and physiological consequences of methamphetamine neurotoxicity: implications for treatment. J Pharmacol Exp Ther. 2017; 362(3): 474-88. [DOI:10.1124/jpet.116.238501]
17. Vallone D, Picetti R, Borrelli E. Structure and function of dopamine receptors. Neurosci Biobehav Rev. 2000; 24(1): 125-32. [DOI:10.1016/S0149-7634(99)00063-9]
18. M Chiu V, O Schenk J. Mechanism of action of methamphetamine within the catecholamine and serotonin areas of the central nervous system. Curr Drug Abuse Rev. 2012; 5(3): 227-42. [DOI:10.2174/1874473711205030227]
19. Panenka WJ, Procyshyn RM, Lecomte T, MacEwan GW, Flynn SW, Honer WG, et al. Methamphetamine use: a comprehensive review of molecular, preclinical and clinical findings. Drug Alcohol Depend. 2013; 129(3): 167-79. [DOI:10.1016/j.drugalcdep.2012.11.016]
20. Ares-Santos S, Granado N, Moratalla R. The role of dopamine receptors in the neurotoxicity of methamphetamine. J Intern Med. 2013; 273(5): 437-53. [DOI:10.1111/joim.12049]
21. Stephans SE, Yamamoto BK. Methamphetamine-induced neurotoxicity: roles for glutamate and dopamine efflux. Synapse. 1994; 17(3): 203-9. [DOI:10.1002/syn.890170310]
22. Larsen KE, Fon EA, Hastings TG, Edwards RH, Sulzer D. Methamphetamine-induced degeneration of dopaminergic neurons involves autophagy and upregulation of dopamine synthesis. J Neurosci. 2002; 22(20): 8951-60. [DOI:10.1523/JNEUROSCI.22-20-08951.2002]
23. Cadet JL, Jayanthi S, Deng X. Speed kills: cellular and molecular bases of methamphetamine-induced nerve terminal degeneration and neuronal apoptosis. Faseb J. 2003; 17(13): 1775-88. [DOI:10.1096/fj.03-0073rev]
24. Sekine Y, Iyo M, Ouchi Y, Matsunaga T, Tsukada H, Okada H, et al. Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am J Psychiatry. 2001; 158(8): 1206-14. [DOI:10.1176/appi.ajp.158.8.1206]
25. Kish SJ. Pharmacologic mechanisms of crystal meth. Can Med Assoc J. 2008; 178(13): 1679-82. [DOI:10.1503/cmaj.071675]
26. Oláh T, Ocsovszki I, Mándi Y, Pusztai R, Bakay M, Balint E. Opposite effects of serotonin and interferon-α on the membrane potential and function of human natural killer cells. In Vitro Cell Dev Biol-Anim. 2005; 41(5): 165-70. [DOI:10.1290/0407048.1]
27. Sekine Y, Ouchi Y, Takei N, Yoshikawa E, Nakamura K, Futatsubashi M, et al. Brain serotonin transporter density and aggression in abstinent methamphetamine abusers. Arch Gen Psychiatry. 2006; 63(1): 90-100. [DOI:10.1001/archpsyc.63.1.90]
28. Schmidt CJ, Somalia PK, Hanson GR, Peat MA, Gibb JW. Methamphetamine-induced depression of monoamine synthesis in the rat: development of tolerance. J Neurochem. 1985; 44(3): 852-5. [DOI:10.1111/j.1471-4159.1985.tb12893.x]
29. Kishi T, Tsunoka T, Ikeda M, Kitajima T, Kawashima K, Okochi T, et al. Serotonin 1A receptor gene is associated with Japanese methamphetamine-induced psychosis patients. Neuropharmacology. 2010; 58(2): 452-6. [DOI:10.1016/j.neuropharm.2009.09.006]
30. Kaushal N, R Matsumoto R. Role of sigma receptors in methamphetamine-induced neurotoxicity. Curr Neuropharmacol. 2011; 9(1): 54-7. [DOI:10.2174/157015911795016930]
31. Hart CL, Marvin CB, Silver R, Smith EE. Is cognitive functioning impaired in methamphetamine users? a critical review. Neuropsychopharmacology. 2012; 37(3): 586-608. [DOI:10.1038/npp.2011.276]
32. Adriani W, Felici A, Sargolini F, Roullet P, Usiello A, Oliverio A, et al. N-methyl-D-aspartate and dopamine receptor involvement in the modulation of locomotor activity and memory processes. Exp Brain Res. 1998; 123(1-2): 52-9. [DOI:10.1007/s002210050544]
33. Thanos PK, Kim R, Delis F, Rocco MJ, Cho J, Volkow ND. Effects of chronic methamphetamine on psychomotor and cognitive functions and dopamine signaling in the brain. Behav Brain Res. 2017; 320: 282-90. [DOI:10.1016/j.bbr.2016.12.010]
34. Simon SL, Domier C, Carnell J, Brethen P, Rawson R, Ling W. Cognitive impairment in individuals currently using methamphetamine. Am J Addict. 2000; 9(3): 222-31. [DOI:10.1080/10550490050148053]
35. Scott JC, Woods SP, Matt GE, Meyer RA, Heaton RK, Atkinson JH, et al. Neurocognitive effects of methamphetamine: a critical review and meta-analysis. Neuropsychol Rev. 2007; 17(3): 275-97. [DOI:10.1007/s11065-007-9031-0]
36. Murnane KS, Perrine SA, Finton BJ, Galloway MP, Howell LL, Fantegrossi WE. Effects of exposure to amphetamine derivatives on passive avoidance performance and the central levels of monoamines and their metabolites in mice: correlations between behavior and neurochemistry. Psychopharmacology. 2012; 220(3): 495-508. [DOI:10.1007/s00213-011-2504-0]
37. Roussotte FF, Bramen JE, Nunez SC, Quandt LC, Smith L, O'connor MJ, et al. Abnormal brain activation during working memory in children with prenatal exposure to drugs of abuse: the effects of methamphetamine, alcohol, and polydrug exposure. Neuroimage. 2011; 54(4): 3067-75. [DOI:10.1016/j.neuroimage.2010.10.072]
38. Henry BL, Minassian A, Perry W. Effect of methamphetamine dependence on everyday functional ability. Addict Behav. 2010; 35(6): 593-8. [DOI:10.1016/j.addbeh.2010.01.013]
39. Paulus MP, Hozack NE, Zauscher BE, Frank L, Brown GG, Braff DL, et al. Behavioral and functional neuroimaging evidence for prefrontal dysfunction in methamphetamine-dependent subjects. Neuropsychopharmacology. 2002; 26(1): 53-63. [DOI:10.1016/S0893-133X(01)00334-7]
40. Thompson PM, Hayashi KM, Simon SL, Geaga JA, Hong MS, Sui Y, et al. Structural abnormalities in the brains of human subjects who use methamphetamine. J Neurosci. 2004; 24(26): 6028-36. [DOI:10.1523/JNEUROSCI.0713-04.2004]
41. Recinto P, Samant ARH, Chavez G, Kim A, Yuan CJ, Soleiman M, et al. Levels of neural progenitors in the hippocampus predict memory impairment and relapse to drug seeking as a function of excessive methamphetamine self-administration. Neuropsychopharmacology. 2012; 37(5): 1275-87. [DOI:10.1038/npp.2011.315]
42. Cadet JL, Krasnova IN. Molecular bases of methamphetamine-induced neurodegeneration. Int Rev Neurobiol. 2009; 88: 101-19. [DOI:10.1016/S0074-7742(09)88005-7]
43. Wang S-F, Yen J-C, Yin P-H, Chi C-W, Lee H-C. Involvement of oxidative stress-activated JNK signaling in the methamphetamine-induced cell death of human SH-SY5Y cells. Toxicology. 2008; 246(2-3): 234-41. [DOI:10.1016/j.tox.2008.01.020]
44. Kuhn DM, Francescutti-Verbeem DM, Thomas DM. Dopamine quinones activate microglia and induce a neurotoxic gene expression profile. Ann N Y Acad Sci. 2006; 1074(1): 31-41. [DOI:10.1196/annals.1369.003]
45. Andres MA, Cooke IM, Bellinger FP, Berry MJ, Zaporteza MM, Rueli RH, et al. Methamphetamine acutely inhibits voltage-gated calcium channels but chronically up-regulates L-type channels. J Neurochem. 2015; 134(1): 56-65. [DOI:10.1111/jnc.13104]
46. Tata DA, Yamamoto BK. Interactions between methamphetamine and environmental stress: role of oxidative stress, glutamate and mitochondrial dysfunction. Addiction. 2007; 102(1): 49-60. [DOI:10.1111/j.1360-0443.2007.01770.x]
47. Cadet JL, Jayanthi S, Deng X. Methamphetamine-induced neuronal apoptosis involves the activation of multiple death pathways. Review Neurotox Res. 2005; 8(3-4): 199-206. [DOI:10.1007/BF03033973]
48. Cadet JL, Ordonez SV, Ordonez JV. Methamphetamine induces apoptosis in immortalized neural cells: protection by the proto‐oncogene, bcl‐2. Synapse. 1997; 25(2): 176-84. https://doi.org/10.1002/(SICI)1098-2396(199702)25:2<176::AID-SYN8>3.0.CO;2-9 [DOI:10.1002/(SICI)1098-2396(199702)25:23.0.CO;2-9]
49. Sekine Y, Ouchi Y, Sugihara G, Takei N, Yoshikawa E, Nakamura K, et al. Methamphetamine causes microglial activation in the brains of human abusers. J Neurosci. 2008; 28(22): 5756-61. [DOI:10.1523/JNEUROSCI.1179-08.2008]
50. Johnson-Davis KL, Fleckenstein AE, Wilkins DG. The role of hyperthermia and metabolism as mechanisms of tolerance to methamphetamine neurotoxicity. Eur J Pharmacol. 2003; 482(1-3): 151-4. [DOI:10.1016/j.ejphar.2003.09.063]
51. Sharma HS, Kiyatkin EA. Rapid morphological brain abnormalities during acute methamphetamine intoxication in the rat: an experimental study using light and electron microscopy. J Chem Neuroanat. 2009; 37(1): 18-32. [DOI:10.1016/j.jchemneu.2008.08.002]
52. Martins T, Baptista S, Gonçalves J, Leal E, Milhazes N, Borges F, et al. Methamphetamine transiently increases the blood–brain barrier permeability in the hippocampus: role of tight junction proteins and matrix metalloproteinase-9. Brain Res. 2011; 1411: 28-40. [DOI:10.1016/j.brainres.2011.07.013]
53. Hsieh JH, Stein DJ, Howells FM. The neurobiology of methamphetamine induced psychosis. Front Hum Neurosci. 2014; 8: 537. doi: 10.3389/fnhum.2014.00537. [DOI:10.3389/fnhum.2014.00537]
54. Hadizade Asar S, Hosseini-Sharifabad M, Yadegari M. A stereological study on hippocampal subfields following administration of methamphetamine in male mice. IJML. 2016; 3(4): 270-81.



XML   English Abstract   Print



دوره 6، شماره 3 - ( تابستان - 1397 ) برگشت به فهرست نسخه ها